Dr. Susan P. Perrine MD, SM, MMS

Expert Publications

• Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo.
• Biochemical effect of intravenous arginine butyrate in X-linked adrenoleukodystrophy.
• Sickle cell anemia is associated with reduced nitric oxide bioactivity in peripheral conduit and resistance vessels.
• Enhancement of growth and survival and alterations in Bcl-family proteins in beta-thalassemic erythroid progenitors by novel short-chain fatty acid derivatives.
• Fetal globin induction--can it cure beta thalassemia?
• Induction of fetal globin in beta-thalassemia: Cellular obstacles and molecular progress.
• Novel short chain fatty acids restore chloride secretion in cystic fibrosis.
• Identification of novel small-molecule inducers of fetal hemoglobin using pharmacophore and 'PSEUDO' receptor models.
• Short-chain fatty acids induce gamma-globin gene expression by displacement of a HDAC3-NCoR repressor complex.
• Liquid chromatography-mass spectrometric assay for quantitation of the short-chain fatty acid, 2,2-dimethylbutyrate (NSC 741804), in rat plasma.
• Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential.
• Effects of divalproex sodium on hemoglobin level.
• A randomized phase II trial of Arginine Butyrate with standard local therapy in refractory sickle cell leg ulcers.
• Short-term toxicity study of ST-20 (NSC-741804) by oral gavage in Sprague-Dawley rats.
• Novel therapeutic candidates, identified by molecular modeling, induce γ-globin gene expression in vivo.

Media Releases

Leading Cutting-Edge Research and Clinical Excellence at Phoenicia BioSciences, Inc. and Beyond

Weston, Massachusetts – Dr. Susan P. Perrine, a distinguished figure in the field of medicine, has been at the forefront of groundbreaking research and clinical advancements in hematology, oncology, and orphan diseases. Serving as the President and Chief Medical Officer at Phoenicia BioSciences, Inc. since August 2008, Dr. Perrine has steered the company towards the discovery and development of cutting-edge therapeutics while fostering strategic industry partnerships and spearheading innovative clinical trial designs.

With an illustrious career spanning over decades, Dr. Perrine's contributions to the medical community are immeasurable. As a Professor of Medicine, Pediatrics, and Pharmacology & Experimental Therapeutics at Boston University Chobanian & Avedisian School of Medicine since March 1994, she has been instrumental in directing translational research and clinical trials aimed at developing novel therapeutics and patient care strategies for various blood diseases.

In addition to her academic role, Dr. Perrine has served as a dedicated pediatric hematologist oncologist at Tufts Medical Center since February 2011, providing specialized medical care to pediatric patients battling blood diseases. Her compassionate approach and commitment to improving patient outcomes have earned her the respect and admiration of colleagues and patients alike.

Dr. Perrine’s academic journey reflects her pursuit of excellence and commitment to advancing medical knowledge. She obtained Master of Science and Master of Public Health degrees from Harvard T.H. Chan School of Public Health before earning her Medical Degree from Tufts University School of Medicine in 1976. Her extensive training includes residencies at Tufts Medical Center and fellowships at Boston Children's Hospital/Boston Medical Center, culminating in board certifications in pediatrics and pediatric hematology-oncology.

Dr. Perrine is an esteemed member of the Boston University-Boston Medical Center Cancer Center and the Institute for Genome Sciences. Her affiliations underscore her dedication to collaboration, research excellence, and advancing the field of hematology and oncology.

Dr. Susan P. Perrine’s relentless pursuit of medical innovation and unwavering commitment to patient care continue to inspire and drive advancements in the field of hematology and oncology. Her visionary leadership and expertise position her as a trailblazer in the medical community, shaping the future of healthcare for generations to come.

Recommended Articles

• UTI Treatments

  Urinary tract infections (UTIs) are the second most common type of infection that can affect the body and the most common nosocomial infection. Given the prevalence of such a condition, you would also expect that there would be more than a few ways to treat them.Treatments for UTIs are available...

• Feds Appropriate $10M to Lupus Foundation for Research

  The Lupus Foundation of America estimates that at least five million people worldwide suffer from any type of lupus. One and a half million of these patients are American women who are at childbearing age, and almost all experience fatigue, pain, cognitive and physical issues, hair loss, and several...

• Purpura

  PurpuraPurpura refers to purple-colored spots that are usually seen on the skin, including mucous membranes and other organs. It is also called skin hemorrhages or blood spots.Purpura is usually recognized when there is pooling of blood under the skin due to ruptured small blood vessels. The size of...

• Potential Causes of Leukopenia

  IntroductionA decrease in the number of white blood cells (WBCs) is referred to as leukopenia. There are several causes for leukopenia. It may be due to certain drugs, cancer, radiation and chemotherapy for cancer, stem cell transplant, surgery, steroids, or autoimmune disorders. The immune system...

• Study Finds 3% of Pediatric Non-Hodgkin Lymphoma Cases Are Transplant Recipients

  Lymphoma is a blood cancer that affects both children and adults.Lymphoma begins its growth in the lymphatic white blood cells of the lymph system. This system is a major warrior in fighting off infections and diseases. It is part of the body’s immunity team.The lymph system loops throughout the...

• How Is Leukemia Diagnosed?

  Leukemia in its early stages may present no signs or symptoms, as these only appear when the leukemia cells have taken over a large number of normal blood cells. A person with leukemia is very lucky indeed if early-stage detection occurs incidentally, through a routine blood test or one done for...